Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether PRO044 is safe and effective to use as medication
for DMD patients with a mutation around location 44 in the DNA for the dystrophin protein.